Heart drug swap tested for safer symptom control

NCT ID NCT07600177

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with a type of heart disease called obstructive hypertrophic cardiomyopathy can safely switch from one medication (mavacamten) to another (aficamten). The goal is to keep the heart working better and reduce symptoms. About 40 adults who are already taking mavacamten will be enrolled and closely monitored for side effects and heart function changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • St. Luke's Hospital - Mid America Heart Institute

    NOT_YET_RECRUITING

    Kansas City, Missouri, 64111, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact